Skip to main content

Tumour Agnostic

UTAAVENT

Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Entrectinib


UTAAVLAR

Treatment of Solid Tumours with Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion using Larotrectinib


The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use.

SOURCE: Tumour Agnostic ( http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols/tumour-agnostic )
Page printed: 2025-03-26 . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © 2025 BC Cancer. All Rights Reserved.

    Copyright © 2025 Provincial Health Services Authority